Other ETFs in the biology trade
ETFs in this story that fit none of the categories above.
10ETFs in this category
$436mmoney in them
0.3%of the biology trade’s money
CANClargest unleveraged ETF, 49.6%
How they did, to Nov 2, 2026
| 1 month | YTD | 12 months | |
|---|---|---|---|
| Category median | +2.3% | +13.4% | +20.5% |
| Its story | +7.5% | +21.0% | +29.0% |
| Broad US ETFs | −2.5% | +11.5% | +11.8% |
Every ETF here, largest first
| # | ETF | Name | Assets | Share | 12 months | Fee |
|---|---|---|---|---|---|---|
| 1 | CANC | Tema Oncology ETF | $216m | 49.6% | +34.6% | 0.75% |
| 2 | SURI | Simplify Propel Opportunities ETF | $76m | 17.4% | +13.2% | 2.56% |
| 3 | HRTS | Tema Heart & Health ETF | $56m | 12.8% | +20.6% | 0.75% |
| 4 | FMED | Fidelity Disruptive Medicine ETF | $54m | 12.5% | +20.3% | 0.50% |
| 5 | MEDX | Horizon Kinetics Medical ETF | $18m | 4.1% | +23.4% | 0.85% |
| 6 | EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | $10m | 2.3% | +27.3% | 0.65% |
| 7 | NVOH | Novo Nordisk A/S (B Shares) ADRhedged | $4m | 0.8% | −11.2% | 0.19% |
| 8 | PEPT | REX Peptide ETF | $2m | 0.4% | – | 0.65% |
| 9 | GSKH | GSK plc ADRhedged | under $1m | 0.2% | +5.5% | 0.19% |
| 10 | AIHC | Tuttle Capital AI Drug Discovery ETF | – | 0.0% | – | – |
Other categories in the biology trade
Common questions
Which ETFs are other ETFs?10 US ETFs sit in this category of the biology trade. ETFs in this story that fit none of the categories above.
What is the largest other ETF?CANC, Tema Oncology ETF, with $216m, 49.6% of the category's money.
How have other ETFs performed?The median unleveraged ETF here returned +20.5% over the last 12 months to Nov 2, 2026, against +11.8% for broad US ETFs. Past performance, not a forecast.